Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 5/20 | 0.31 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.30 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.30 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.30 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.30 |
| ▸ | CHRNA10 | Q9GZZ6 | 1/20 | 0.30 |
| ▸ | CHRNA9 | Q9UGM1 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15041153 | 0.99 | CHRNA7 (0.32) | CHRNA7CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL15041145 | 0.92 | CHRM2 (0.33) | — | |
| SCHEMBL15041154 | 0.90 | CHRM2 (0.35) | CHRNA7CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL15546579 | 0.88 | CASP1 (0.31) | CHRNA7ALDH1A1HPGDKMT2A | |
| SCHEMBL15041155 | 0.87 | CHRNB2 (0.34) | CHRNA7CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL15546616 | 0.87 | CHRNA7 (0.32) | CHRNA7CHRNB2CHRNA4ALDH1A1HPGD | |
| SCHEMBL14785141 | 0.86 | LMNA (0.37) | ALDH1A1HPGDKMT2A | |
| SCHEMBL14785276 | 0.85 | LMNA (0.39) | CHRNA7CHRNB2CHRNA4ALDH1A1HPGD | |
| SCHEMBL15545661 | 0.80 | CHRM2 (0.33) | — | |
| SCHEMBL15041148 | 0.80 | HPGD (0.35) | CHRNA7CHRNB2CHRNB4CHRNA3CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150150766-A1 | CATIONIC PARA-PHENYLENEDIAMINES, COMPOSITION COMPRISING AT LEAST SUCH COMPOUNDS, IMPLEMENTATION PROCESS THEREFOR AND USE THEREOF | L'OREAL (FR) | 2015-06-04 | — | — | US | disclosed |
| WO-2013087934-A1 | CATIONIC PARA-PHENYLENEDIAMINES, COMPOSITION COMPRISING AT LEAST SUCH COMPOUNDS, IMPLEMENTATION PROCESS THEREFOR AND USE THEREOF | L'OREAL (FR) | 2013-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150150766-A1 | CATIONIC PARA-PHENYLENEDIAMINES, COMPOSITION COMPRISING AT LEAST SUCH COMPOUNDS, IMPLEMENTATION PROCESS THEREFOR AND USE THEREOF | KRT18, PPHLN1, PPIF | CHRNA7 1923/4885CHRNB2 2182/4885CHRNB4 1822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.